Units from France’s Carmat sold in Europe

Artificial hearts that can prove to be a lifeline for those suffering from fatal heart failure will be sold in Europe after the units from the French company Carmat have been approved.

Carmat says it now plans to start selling its artificial heart, called Aeson, in the second quarter of this year.

The device is designed to mimic a real heart with biological materials and sensors.

It weighs 900 g and is powered by batteries and acts mainly as a mechanical pump to regulate blood flow.

“The idea behind this heart, which was born almost 30 years ago, was to create a device that would replace heart transplants, a device that functions physiologically as a human heart, one that is pulsating, self-regulating and compatible with blood,” Stéphane Piat, Carmats CEO, told Reuters.

The device is designed to replace a true heart for several years in patients with end-stage biventricular heart failure. But at present it has only been approved as a temporary implant for those waiting for a heart transplant.

Heart disease is a leading cause of death worldwide and a lack of donors for transplants is a common problem.

According to several estimates, approximately 2,000 biventricular heart failure patients are on waiting lists for transplantation across Western Europe.